Taiwan · Delayed Price · Currency is TWD Libo Pharma Statistics
Total Valuation
Libo Pharma has a market cap or net worth of TWD 3.36 billion. The enterprise value is 2.56 billion.
| Market Cap | 3.36B |
| Enterprise Value | 2.56B |
Important Dates
The next estimated earnings date is Thursday, June 18, 2026.
| Earnings Date | Jun 18, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Libo Pharma has 75.24 million shares outstanding. The number of shares has increased by 33.65% in one year.
| Current Share Class | 75.24M |
| Shares Outstanding | 75.24M |
| Shares Change (YoY) | +33.65% |
| Shares Change (QoQ) | +1.18% |
| Owned by Insiders (%) | 4.73% |
| Owned by Institutions (%) | n/a |
| Float | 63.53M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| PB Ratio | 3.17 |
| P/TBV Ratio | 3.68 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -8.64 |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -7.32 |
Financial Position
The company has a current ratio of 43.19, with a Debt / Equity ratio of 0.00.
| Current Ratio | 43.19 |
| Quick Ratio | 37.40 |
| Debt / Equity | 0.00 |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.00 |
| Interest Coverage | -7,708.10 |
Financial Efficiency
Return on equity (ROE) is -39.01% and return on invested capital (ROIC) is -25.30%.
| Return on Equity (ROE) | -39.01% |
| Return on Assets (ROA) | -24.86% |
| Return on Invested Capital (ROIC) | -25.30% |
| Return on Capital Employed (ROCE) | -29.06% |
| Weighted Average Cost of Capital (WACC) | n/a |
| Revenue Per Employee | n/a |
| Profits Per Employee | -14.81M |
| Employee Count | 20 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
| Beta (5Y) | n/a |
| 52-Week Price Change | n/a |
| 50-Day Moving Average | 49.45 |
| 200-Day Moving Average | n/a |
| Relative Strength Index (RSI) | 40.77 |
| Average Volume (20 Days) | 51,666 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -308.32M |
| Pretax Income | -296.30M |
| Net Income | -296.30M |
| EBITDA | -284.78M |
| EBIT | -308.32M |
| Earnings Per Share (EPS) | -4.74 |
Balance Sheet
The company has 801.03 million in cash and 1.32 million in debt, with a net cash position of 799.70 million or 10.63 per share.
| Cash & Cash Equivalents | 801.03M |
| Total Debt | 1.32M |
| Net Cash | 799.70M |
| Net Cash Per Share | 10.63 |
| Equity (Book Value) | 1.06B |
| Book Value Per Share | 12.65 |
| Working Capital | 905.51M |
Cash Flow
In the last 12 months, operating cash flow was -349.10 million and capital expenditures -558,000, giving a free cash flow of -349.66 million.
| Operating Cash Flow | -349.10M |
| Capital Expenditures | -558,000 |
| Depreciation & Amortization | 23.55M |
| Net Borrowing | -1.66M |
| Free Cash Flow | -349.66M |
| FCF Per Share | -4.65 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Libo Pharma does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -33.65% |
| Shareholder Yield | -33.65% |
| Earnings Yield | -8.82% |
| FCF Yield | -10.41% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |